NPIL's Hyderabad-based plant is one of the very few USFDA site-approved plants in India, is capable of all types of reactions. The plant is unique in that it has USFDA approval for the entire facility and not merely a product line, without and deficiency or non-conformity i.e. without any 483s. It is also accredited and approved by MCA of UK, TGA of Australia and the European and Canadian Drug Authorities.

The company's state-of-the-art plant at Pithampur in Central India is reckoned among the finest in this part of the world. Accredited by reputed organizations, the plant also does toll manufacturing for reputed MNCs like Allergan, Novartis, Solvay and IVAX, in addition to a host of leading Indian companies.

The state-of-the-art domestic formulations plant, built at a cost of Rs1.6bn. was commissioned in 2006 in a record twelve months.

NPIL has in place all the key capabilities critical to this business - manufacturing, process development (integrating with R&D), IPR protection, BD and supply chain management.

Significantly, NPIL is also well placed to offer manufacturing services across the entire life cycle of a product, including the development stage. Our capabilities today include not just lower cost dosage manufacturing, but the ability to manage costs through process innovation and the skills to aid in formulations R&D development and New Drug Delivery Systems.